GlaxoSmithKline vaccine receives recommendation from FDA

GlaxoSmithKline’s cervical cancer vaccine Cervarix has been the subject of a positive recommendation from the Food and Drug Administration (FDA), it has been revealed.

The FDA’s Vaccines and Related Biological Products Advisory Committee voted that the trial data supports Ceravix’s efficacy and safety.

During the study, it was determined that the vaccine was well-tolerated and highly effective in young women and girls when it comes to the tackling of cervical pre-cancers and cervical cancer related to human papillomavirus types 16 and 18.

Barbara Howe, vice-president and director of vaccine development for GlaxoSmithKline, commented: “If approved, Ceravix will provide protection against cervical cancer, a devastating disease that is responsible for thousands of deaths […] each year.”

This news follows the announcement in August that GlaxoSmithKline is to partner with the Oswaldo Cruz Foundation (Fiocruz), to develop and manufacture vaccines for a variety of conditions, including dengue fever.